⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Pegozafermin (Pegozafermin) | 加速させる、線維化研究を

Home/Drugs/Pegozafermin

Pegozafermin

Pegozafermin

Phase 3

Sponsor: 89bio

Indication: MASH

Mechanism of Action

FGF21 Analog

Target: FGF21

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT04048135

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

Phase:PHASE1, PHASE2Org:89bio, Inc.

RECRUITING

Relevant Publications (PubMed)

No recent publications found for Pegozafermin.

Validated Models

This drug has been validated in the following preclinical models:

NCT06419374

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Phase:PHASE3Org:89bio, Inc.

RECRUITINGNCT06318169

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Phase:PHASE3Org:89bio, Inc.

COMPLETEDNCT04929483

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

Phase:PHASE2Org:89bio, Inc.

COMPLETEDNCT04541186

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

Phase:PHASE2Org:89bio, Inc.

View all trials on ClinicalTrials.gov